HR-NLB1: Busulphan/melphalan improved 3-year OS to 60% in pediatric neuroblastoma

  • HemOnc Today, July 25, 2011

2011 ASCO Annual Meeting

CHICAGO — Children with hard-to-treat neuroblastoma assigned to myeloablative chemotherapy with busulphan and melphalan had better OS and event-free survival compared with patients assigned to a myeloablative regimen of carboplatin, etoposide and melphalan.

More »

Additional headlines from 2011 ASCO Annual Meeting

See All »

Recent Meetings

[X]